Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomics

Background: In the context of hormone receptor positive, HER2 negative Metastatic breast cancer (MBC), CDK 4/6 inhibitors (CDK4/6i) combined with endocrine therapy represent the standard first-line treatment, improving Progression-Free Survival (PFS) and Overall Survival (OS). Despite these benefits...

Full description

Saved in:
Bibliographic Details
Main Authors: Lorenzo Foffano, Alessandra Franzoni, Elisabetta Molteni, Fabiola Giudici, Arianna Dri, Debora Basile, Linda Cucciniello, Silvia Buriolla, Claudia Noto, Stefania Russo, Elena Nascimbeni, Silvia Bolzonello, Brenno Pastò, Serena Della Rossa, Lorenzo Allegri, Marta Bonotto, Alessandro Marco Minisini, Barbara Belletti, Giuseppe Damante, Lorenzo Gerratana, Fabio Puglisi
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Translational Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325001871
Tags: Add Tag
No Tags, Be the first to tag this record!